Results 81 to 90 of about 216,339 (397)

The Role of Bevacizumab in Glioblastoma [PDF]

Journal of the National Comprehensive Cancer Network, 2014
Glioblastoma (GBM) is the deadliest and most aggressive of the primary brain malignancies. Outcomes for patients remain poor, with the course of the disease often associated with significant neurologic morbidity because of tumor location within the central nervous system (CNS).
openaire   +3 more sources

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

FEBS Open Bio, EarlyView.
CAF‐mediated immunosuppression in ovarian cancer is driven by IDO1, reducing T‐cell function. Inhibiting IDO1 restores T‐cell proliferation and cytotoxicity, increases cancer cell apoptosis, and may help overcome CAF‐induced immune suppression in high‐grade serous ovarian cancer. Targeting IDO1 may improve antitumor immunity.
Hyewon Lee, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi   +3 more
wiley   +1 more source

Combining Bevacizumab with Endostatin Gets Better Antitumor Efficacy in Vivo 
in Lung Cancer Animal Model

Chinese Journal of Lung Cancer, 2013
Background and objective The aim of this study is to investigate difference of antiangiogenesis ablility and interaction about bevacizumab and endostatin in vivo in lung cancer animal model.
Niu NIU, Baolan LI, Chaoyang LIU, Ying HU, Xuebing LI, Jie LI, Heling SHI, Haiqing ZHANG   +7 more
doaj   +1 more source

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Journal of Clinical Oncology, 2019
PURPOSE We report the final, protocol-specified analysis of overall survival (OS) in GOG-0218, a phase III, randomized trial of bevacizumab in women with newly diagnosed ovarian, fallopian tube, or primary peritoneal carcinoma. METHODS A total of 1,873
K. Tewari, R. Burger, Danielle M. Enserro, B. Norquist, E. Swisher, M. Brady, M. Bookman, G. Fleming, Helen Q. Huang, H. Homesley, J. Fowler, B. Greer, M. Boente, S. Liang, C. Ye, C. Bais, L. Randall, J. Chan, J. Ferriss, R. L. Coleman, C. Aghajanian, T. Herzog, P. Disaia, L. Copeland, R. Mannel, M. Birrer, B. Monk   +26 more
semanticscholar   +1 more source

SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High‐Grade Gliomas: A Multicenter, Open‐Label Phase I Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Recurrent high‐grade gliomas have a poor prognosis and limited therapeutic options. This study aimed to evaluate the safety and efficacy of SYHA1813, a dual inhibitor of VEGFR and CSF1R, in patients with recurrent high‐grade gliomas.
Zhuang Kang, Shenglan Li, Liang Wang, Qianxue Chen, Weiguo Hu, Ting Lei, Ying Mao, Jing Zhang, Xiaojun Xiang, Qiming Wang, Zhengwen He, Tao Sun, Yulei Wang, Mengqian Huang, Rong Zhang, Feng Chen, Wenbin Li   +16 more
wiley   +1 more source

Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study

BMC Cancer, 2011
Background We describe early dissemination patterns for first-line bevacizumab given for metastatic colorectal cancer treatment. Methods We analyzed patient surveys and medical records for a population-based cohort with metastatic colorectal cancer ...
Fouad Mona N, Weeks Jane C, Zullig Leah L, Kolimaga Jane T, Schrag Deborah, Abbott David H, Grambow Steven C, Malin Jennifer L, Zafar S Yousuf, Ayanian John Z, Wallace Robert, Kahn Katherine L, Ganz Patricia A, Catalano Paul, West Dee W, Provenzale Dawn   +15 more
doaj   +1 more source

Bevacizumab‐associated intestinal perforation and perioperative complications in patients receiving bevacizumab

Annals of Gastroenterological Surgery, 2020
Aim The purposes of this study are to present cases of emergency surgery in which gastrointestinal perforation occurred during bevacizumab administration, consider the indications for emergency surgery, and examine the safety of scheduled surgery after a
Toshiaki Yoshimoto, Kozo Yoshikawa, Jun Higashijima, Tomohiko Miyatani, Takuya Tokunaga, Masaaki Nishi, Chie Takasu, Hideya Kashihara, Yukako Takehara, Mitsuo Shimada   +9 more
doaj   +1 more source

Flow‐Induced Vascular Remodeling on‐Chip: Implications for Anti‐VEGF Therapy

Advanced Functional Materials, EarlyView.
Flow‐induced vascular remodeling plays a critical role in network stabilization and function. Using a vasculature‐on‐chip system, this study reveals how physiological VEGF levels and flow affect vascular remodeling and provides insights into tumor vessel normalization.
Fatemeh Mirzapour‐Shafiyi, Elias Huber, Leonie Karr, Johnny Tong, Andreas Richard Bausch, Friedrich Christian Simmel, Karen Alim   +6 more
wiley   +1 more source

Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma

Frontiers in Immunology, 2020
Highly sensitive reporter-gene assays have been developed that allow both the direct vascular endothelial growth factor (VEGF) neutralizing activity of bevacizumab and the ability of bevacizumab to activate antibody dependent cellular cytotoxicity (ADCC)
Christophe Lallemand, Rosa Ferrando-Miguel, Michael Auer, Sarah Iglseder, Theresa Czech, Anouk Gaber-Wagener, Franziska Di Pauli, Florian Deisenhammer, Michael G. Tovey   +8 more
doaj   +1 more source